期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

双源CT在冠心病PCI术后复查中应用 被引量：1

下载PDF
导出
摘要 目的研究双源CT(DSCT)在冠状动脉PCI术后诊断患者冠状动脉狭窄的可行性和可靠性。方法选取进行PCI术后的冠心病患者45例,进行双源CT诊断,以侵入性的冠状动脉造影(ICA)为标准,评估双源CT在冠心病PCI术后的诊断效果。入选患者均进行DSCT和ICA两种检查,两项检查在同一时间段内完成,时间间隔不超过1个月。结果 ICA与DSCT分别诊断正常或无意义的冠状动脉狭窄患者41及44例,有意义的冠状动脉为4及1例,二者结果间差异均无统计学意义(P>0.05)。结论 DSCT与ICAD在诊断冠心病PCI术后冠状动脉狭窄方面均具有一定的疗效,DSCT创伤小、适用范围广,操作简便,认为DSCT可以作为一种筛选冠状动脉狭窄的检查手段。
作者 廖波
机构地区 广西玉林市第一人民医院心内科
出处 《中国医药指南》 2011年第15期275-276,共2页 Guide of China Medicine
关键词 双源CT 冠心病 PCI术后 冠状动脉造影
分类号 R541.4 [医药卫生—心血管疾病]
  • 相关文献

参考文献4

  • 1陈磊磊,龙明智.PTCA术后再狭窄的预防及治疗进展[J].医学综述,2003,9(9):528-531. 被引量：10
  • 2Hofmann R,Bardeleben S,Kasprzak JD,et al.Analysis of Regional Left Ventricular Function by Cineventrieulography,Cardiac Magntic Resonance Imaging,and Unenhanced and Contrast-Enhanced Echocardiography[J].J Am Coll Cardiol,2006,47(1):121-128.
  • 3Thorn T,Haase N,Rosamond W,et al.Heart disease and stroke statistics-2006 update:a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee[J].Circalation,2006,113(6):e85-e151.
  • 4Dikkem R,Greuter MJ,Kristanto W,et al.Assessment of image quality of 64-row Dual Source versus Single Source CT coronary angiography on heart rate:a phantom study[J].Eur J Radiol,2009,70(1):61-68.

二级参考文献16

  • 1Havdhammax PA, van Beusekom HM, Emanuelsson HU, et al. Reduction in thrimbitic events with heparin-coated Palmaz-schatz stent in normal porcine coronary artery[J]. Circulation, 1996,93(3):423-430.
  • 2Toheng JE. Glycoprotein II b/III a receptor inhibitors : putting the EPIC IMPACT II , RESTORE,and EPILOG trails into perspective[J]. Am J Cardiol, 1996,78(3A):35-40.
  • 3Anonymous. Randomized placebo-controlled trail of effect of eptilibatide on complications of percutaneous coronary intervention : IMPACT-II Integrilin to Minimize platelet Aggregation and Coronary Thrombosis-II[J] . Lancet, 1997,349(9063):1422-1428.
  • 4Treasure CB, Klein JL,Weintraub WS,et al. Benifical effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease[J]. NEJM, 1995,332(8):481-487.
  • 5Jukema JW, Bruschke AVG, van Broven A J, et al. ON behalf to the REGRESS study group, Inter University Cardiology Institute Utrecht,the Netherlands. Effects of Lipid Lowerlngby pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated senn cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS)[J]. Circulation, 1995,91(10):2528-2540.
  • 6Jorgensen B, Simonsen S, Endresen K, et ol. Restenosis and clinical outcome in patients treated with Amlodipine after angioplasty: results from CAPARES[J].Am Coil Cardiol, 2000,35(3):592-599.
  • 7Tulenko TN, Brown J, Laury-Kleintop L, et al. Atheroprotection with amlodipine:cells to lesions and the PREVENT trial[J]. J Cardiovasc Parmacol, 1999,33[Suppl 2]:S17-S22.
  • 8Eickelberg O, Roth M ,Block LH. Effects of amlodipine on gene expression and extracellular matrix formation in human vascular smooth muscle cells and fibmblasts: implication for vascular protection[J]. Int J Cardiol, 1997,62[Suppl 2]:S31-S37.
  • 9Watanabe K, Sekiya M, Ikeda S, et al. Prevention effects of probucol on restenosis after percutaneous transluminal coronary angioplasty[J]. Am Heart J,1996,132(1 Pt 1):23.
  • 10Tarif JC, Cote G, Lesperance J, et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty[J]. N Engl J Med,1997,337(6):365.

共引文献9

同被引文献31

  • 1赵冬,刘群.中国冠心病二级预防架桥工程进展——初步调查结果分析报告[J].中华医学信息导报,2007,22(1):19-19. 被引量：18
  • 2Ahem RM, Lozano R, Naghavi M, et al. Improving the public health utility of global cardiovascular mortality data : the rise of isehemic heart disease[J]. Popul Health Metr,2011,9:8. DOI: 10. 1186/ 1478-7954-9-8.
  • 3Mendes A. Coronary heart disease:self-care, communication and quality of life[J]. Br J Connnunity Nurs,2015,20( 1 ) :42. DOI: 10. 12968/bjcn. 2015.20.1.42.
  • 4Prior L, Wilson J, Donnelly M, et al. Translating policy into practice : a case study in the secondary prevention of coronary heart disease[ J ]. Health Expect, 2014, 17 (2) : 291-301. DOI: 10. 1111/j. 1369-7625. 2011. 00754. x.
  • 5Matthias AT, Lokunarangoda NC, Ekanayaka R. Knowledge assessment regarding secondary prevention of coronary heart disease- a multi centre survey[ J]. BMC Medical Education ,2014, 14:113. DOI: 10. 1186/1472-6920-14-113.
  • 6Stone GW, Aronow HD. Long-term Care After Percutaneous Coronary Intervention: Focus on the Role of Antiplatelet Therapy [ J ]. Mayo Clinic Proceedings, 2006,81 ( 5 ) : 641-652. DOI : 10. 4065/81 5. 641.
  • 7Yusuf S, Islam S, Chow CK, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study ):a prospective epidemiological survey [ J ]. Lancet,2011,378 ( 9798 ) : 1231-1243. DOI:10. 1016/S0140-6736 (11)61215-4.
  • 8王强.冠脉支架术后患者支架内再狭窄原因的回顾性研究[D].苏州:苏州大学,2012.
  • 9Kotseva K, Wood D, De Bacquer D, et al. EUROASPIRE IV:A Europe.an Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries[ J]. Eur J Prey Cardiol, 2016,23 ( 6 ) : 636- 648. DOI : 10.1177/2047487315569401.
  • 10Michal M, Simon P, God T, et al. Psychodynamic Motivation and Training program (PMT) for the secondary prevention in patients with stable coronary heart disease : study protocol for a randomized controlled trial of feasibility and effects [J]. Trials, 2013, 14: 314. DOI : 10.1186/1745 -6215-14-314.

引证文献1

二级引证文献8

中国医药指南
2011年 第15期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部